Stockman Wealth Management, Inc. Compugen LTD Transaction History

Stockman Wealth Management, Inc.

$623 Million
Q3 2024

A detailed history of Stockman Wealth Management, Inc. transactions in Compugen LTD stock. As of the latest transaction made, Stockman Wealth Management, Inc. holds 16,000 shares of CGEN stock, worth $24,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,000

Previous 16,000 -0.0%

Holding current value

$24,160

Previous $26,000 7.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$1.68 - $2.52 $8,400 - $12,600	-5,000 Reduced 23.81%	16,000 $26,000
Q4 2023 Feb 01, 2024	SELL	$0.53 - $2.0 $2,120 - $8,000	-4,000 Reduced 16.0%	21,000 $41,000
Q3 2023 Oct 31, 2023	SELL	$0.88 - $1.31 $11,616 - $17,292	-13,200 Reduced 34.55%	25,000 $23,000
Q2 2023 Aug 02, 2023	SELL	$0.57 - $1.38 $17,499 - $42,366	-30,700 Reduced 44.56%	38,200 $43,000
Q1 2023 May 04, 2023	SELL	$0.68 - $1.11 $1,292 - $2,109	-1,900 Reduced 2.68%	68,900 $48,000
Q4 2022 Feb 07, 2023	BUY	$0.58 - $1.2 $41,064 - $84,960	70,800 New	70,800 $50,000
Q2 2022 Jul 28, 2022	SELL	$1.57 - $3.33 $100,166 - $212,454	-63,800 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$14.16 - $19.45 $903,408 - $1.24 Million	63,800 New	63,800 $1.04 Million
Q2 2019 Aug 08, 2019	SELL	$2.8 - $4.14 $193,480 - $286,074	-69,100 Closed	0 $0
Q1 2019 May 07, 2019	BUY	$2.35 - $4.19 $162,385 - $289,529	69,100 New	69,100 $286,000
Q3 2017 Nov 14, 2017	SELL	$2.75 - $3.95 $247,775 - $355,895	-90,100 Closed	0 $0
Q2 2017 Aug 09, 2017	BUY	N/A	90,100	90,100 $342,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.1M

Call Options Held

79.2K

Put Options Held

12.7K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $131M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stockman Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stockman Wealth Management, Inc. with notifications on news.

Account

Stockman Wealth Management, Inc. Compugen LTD Transaction History